Mass Tort brief
PFAS Cleanup Deals, Catheter Verdicts, and GLP-1 Science Gatekeeping
Chemical manufacturers face 15-year cleanup payouts, Becton Dickinson faces mounting bellwether pressure, and federal courts evaluate GLP-1 expert science.
Mass Tort
A $455M North Carolina settlement shows chemical makers face long-term structural payouts — forcing companies into decades of municipal water cleanup costs.
BackgroundPer- and polyfluoroalkyl substances (PFAS) are long-lasting industrial chemicals linked to health risks including cancer and thyroid disease. Municipalities nationwide have filed hundreds of environmental lawsuits against chemical manufacturers to fund water treatment infrastructure.
- Chemours will cover 50% of settlement obligations while DuPont and Corteva split the remaining half under existing corporate liability agreements.
- The agreement resolves contamination claims for North Carolina local governments that were excluded from earlier national water system class settlements.
- Settlement payouts will finance municipal water filtration infrastructure and regional environmental restoration efforts over a 15-year period.
Mass Tort
A $40M bellwether verdict hands plaintiffs crucial leverage — pressuring Becton Dickinson toward a global settlement across 4,000 catheter claims.
BackgroundBard PowerPorts are implanted vascular catheter devices used to deliver medications directly into blood vessels. Nearly 4,000 personal injury lawsuits are consolidated in federal multidistrict litigation alleging port catheter fractures cause severe internal organ damage.
- The plaintiff required emergency surgical intervention after fractured silicone catheter pieces migrated directly into her heart chambers.
- The verdict marks the first major plaintiff trial victory following a deadlocked outcome in the initial bellwether case.
- Becton Dickinson faces thousands of remaining consolidated federal claims scheduled for additional bellwether trials through 2027.
Mass Tort
Rule 702 hearings will determine whether 3,900 GLP-1 injury claims reach juries — making this expert science review a make-or-break hurdle.
BackgroundMultidistrict litigation consolidates over 3,900 personal injury lawsuits against drugmakers Novo Nordisk and Eli Lilly. Plaintiffs allege GLP-1 weight-loss medications cause severe gastroparesis and intestinal obstructions.
- Federal Judge Karen Spencer Marston is reviewing expert testimony regarding general medical causation between GLP-1 medications and gastroparesis.
- Novo Nordisk and Eli Lilly contend that stomach paralysis risks are rare and fully disclosed on drug safety labels.
- An adverse gatekeeping ruling could dismiss thousands of claims, while a favorable ruling clears the path for bellwether jury trials.
Mass Tort
Concora's $9.38 million TCPA settlement resolves non-consent robocall claims — handing affected consumers cash payouts up to $650.
BackgroundThe Telephone Consumer Protection Act restricts automated robocalls and artificial voice messages sent to consumer mobile phones without consent. Class action lawsuits enforcing TCPA statutory damages routinely yield million-dollar corporate settlements.
- Class members submitting valid claims are expected to receive individual cash payouts ranging between $250 and $650.
- Concora Credit denied wrongdoing but agreed to establish the settlement fund to conclude prolonged litigation exposure.
- Claimants have until the October 19 deadline to submit valid online claim documentation through the settlement site.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
